Breaking News

Novartis, Carisma Ink Mfg. Pact for HER 2 Targeted CAR-M Cell Therapy

Initial agreement covers reservation of Novartis' state-of-the-art cell and gene facility in Morris Plains, NJ.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Novartis has signed an initial agreement with Carisma Therapeutics, a biopharmaceutical pioneer in engineered macrophage-based therapeutics, to manufacture the HER 2 targeted CAR-M cell therapy, which is tested in initial trials for the treatment of solid tumors.   The Carisma Therapeutics manufacturing process will be transferred to the Novartis Cell Therapy Site in Morris Plains, NJ, in the coming days. Clinical manufacturing is planned to begin in 2023.   “The Global Biotech Cooperations ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters